Keywords: Biosimilars, Rituxan, MabThera, Herceptin, Erbtux, Roche, Bristol-Myers, Merck KGaA

Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will erode $8.2 billion in US and European sales in 2018

Article | 17 September 2009

Print This

The US and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera (rituximab), Bristol-Myers ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in